Empagliflozin Improves Mitochondrial Biogenesis and Ameliorates Experimental Pulmonary Vascular Remodeling, But May Not Benefit Patients with Pulmonary Arterial Hypertension
Keimei Yoshida, Eszter Margit Tóth, Erik Duijvelaar, Beau Neep et autres
Abstract Background The sodium glucose cotransporter 2 (SGLT2) inhibitor may improve mitochondrial biogenesis and attenuate pulmonary vascular remodeling in pulmonary arterial hypertension (PAH). We investigated the impact of empagliflozin in PAH. Methods Lung sections and primary cell cultures isolated from microvascular endothelial …
jp, nl, us (code pays fourni par la source)